News

  • Clear filters
Industry | 6th May, 2015
Dr Nicola Broughton joins MFM as Investment Director and Head of Technology Transfer
| 5th May, 2015
Virtual Reality – the magic of feeling, not watching
Direct Investments | 5th May, 2015
The impact of technology on social care
Direct Investments | 5th May, 2015
Crowd Reactive launches EventsTag service for care homes
Events | 29th April, 2015
St Andrews-based Razorbill Instruments wins Mercia Fund Management’s Q1 Business Plan Competition
Events | 29th April, 2015
Mercia Fund Management launches start-up competition for Life Sciences sector
| 28th April, 2015
St Andrews-based Razorbill Instruments wins MFM’s Q1 Business Plan Competition
Mercia EIS Funds | 28th April, 2015
Mercia launches start-up competition for Life Sciences sector
Industry | 23rd April, 2015
‘SWL Australia’ opens for business
Direct Investments | 16th April, 2015
PsiOxus Therapeutics expands clinical studies for immuno-oncolytic treatment following positive response to intravenous delivery
Direct Investments | 16th April, 2015
PsiOxus Therapeutics to present promising new data on novel oncolytic immunocology platform at AACR 2015
Corporate | 1st April, 2015
£3.5m investment in leading e-procurement platform, Science Warehouse, increases Mercia’s stake
Direct Investments | 1st April, 2015
£1m investment in Soccer Manager Ltd
Corporate | 25th March, 2015
Matt Mead appointed Chief Investment Officer
Direct Investments | 19th March, 2015
Looking forward: Our first month as a PLC
Direct Investments | 19th March, 2015
VirtTrade confirms partnership agreement with Panini
Direct Investments | 18th March, 2015
£1m investment in user-generated content platform, Crowd Reactive
Corporate | 17th February, 2015
Two more universities become investors in Mercia Technologies
Corporate | 17th February, 2015
Peter Dines joins Mercia as Investment Director, Head of Life Sciences
Corporate | 17th February, 2015
Mercia Fund Management wins the double at the EISA Awards
Direct Investments | 16th February, 2015
Completion of Mercia Fund 2 acquisition
Direct Investments | 27th January, 2015
£1.5m investment in digital trading card company, VirtTrade
Direct Investments | 22nd January, 2015
Notice of Mercia Fund Management AGM
| 20th January, 2015
Mercia’s £70m flotation wins deal of the month
Direct Investments | 20th January, 2015
Investment in nDreams
Mercia EIS Funds | 14th January, 2015
Startup competition launches
Direct Investments | 14th January, 2015
Martin Lamb appointed as a non-executive director
Industry | 19th November, 2014
Virtual Reality set to deliver a ‘seismic change’ within the gaming industry
Mercia EIS Funds | 13th November, 2014
Investing in gaming start-ups
Mercia EIS Funds | 8th October, 2014
Edge Case Games investment
Mercia EIS Funds | 26th September, 2014
Soccer Manager
Mercia EIS Funds | 25th September, 2014
Aston Eyetech investment
Mercia EIS Funds | 18th September, 2014
Mercia makes £229,000 investment in Inocardia
Mercia EIS Funds | 18th September, 2014
Mercia makes automotive sector investment in Impressions Technologies Ltd
| 27th August, 2014
Tutortap wins Mercia’s Investment Pitch
Mercia EIS Funds | 24th August, 2014
Abzena IPO
Mercia EIS Funds | 15th August, 2014
Mercia Digital Fund launch
Mercia EIS Funds | 30th July, 2014
Oxford Genetics secures additional funding from Mercia and TSB
Mercia EIS Funds | 21st July, 2014
Mercia Fund Management makes £229,000 investment in InoCardia
Mercia EIS Funds | 17th July, 2014
Finance Bill should boost Britain’s world-leading technology firms
Mercia EIS Funds | 11th July, 2014
Abzena float represents a profitable return for Mercia’s investors
Mercia EIS Funds | 9th July, 2014
Abzena raises £20 million in connection with forthcoming admission to AIM
Mercia EIS Funds | 18th June, 2014
Abzena intention to float
Mercia EIS Funds | 10th June, 2014
Mercia Fund Management makes £150,000 investment in Dab Gaming
Mercia EIS Funds | 6th June, 2014
Antitope and Baylor Institute for Immunology Research to Collaborate to Produce Manufacturing Cell Line for Novel Therapeutic Dendritic-cell-targeting Vaccine
Mercia EIS Funds | 4th June, 2014
Mercia Fund Management launches start-up competition
Mercia EIS Funds | 3rd June, 2014
PsiOxus Therapeutics announces positive study results of oncolytic vaccine enadenotucirev at 2014 ASCO Annual Meeting
Mercia EIS Funds | 27th May, 2014
PolyTherics and Antitope form Abzena
Mercia EIS Funds | 19th May, 2014
BioExtractions Wales completes funding round for innovative extraction service
Mercia EIS Funds | 14th May, 2014
Mercia Fund Management launches flexible, cost effective workspace for early stage gaming and technology businesses
Mercia EIS Funds | 12th May, 2014
Mercia Fund Management agrees second stage funding for VirtTrade
Mercia EIS Funds | 8th May, 2014
Mercia Fund Management backs social media duo Crowd Reactive and TorqBak
Mercia EIS Funds | 29th April, 2014
Thalia Design Automation Ltd completes A round funding and prepares to launch suite of Analog and Power design optimisation tools
Mercia EIS Funds | 25th April, 2014
Mercia Fund Management boosts portfolio with Canary investment
Mercia EIS Funds | 23rd April, 2014
Mercia mention in FT.com “Getting exposure to UK tech”
Mercia EIS Funds | 11th April, 2014
PolyTherics and MacroGenics extend Collaboration to Produce Novel Antibody Drug Conjugates
Mercia EIS Funds | 7th April, 2014
Mercia Fund Management makes gaming sector investments in nDreams and No Yetis Allowed
Mercia EIS Funds | 2nd April, 2014
Concurrent Thinking secures £400,000 funding boost
Mercia EIS Funds | 28th March, 2014
Mercia Fund Management boosts digital portfolio with DMPortal investment
Mercia EIS Funds | 19th March, 2014
Budget 2014 – SEIS is now permanent as tax breaks for investment in SMEs continue
Mercia EIS Funds | 17th March, 2014
Budget: keep tax incentives to encourage investment in SMEs urges VC fund manager
Mercia EIS Funds | 13th March, 2014
Mercia mention in FT Adviser Guide to Enterprise Investment Schemes (EIS)
Mercia EIS Funds | 12th March, 2014
IFA Magazine – Time is geting tight to invest in EIS for this tax year
Mercia EIS Funds | 28th February, 2014
Mercia Fund Management ups its game with former Codemasters CEO appointment
Mercia EIS Funds | 19th February, 2014
Smart Antenna Technologies secures extra funding
Mercia EIS Funds | 7th February, 2014
IFA Magazine – EIS investment is on the rise, but where is the capital being allocated?
Mercia EIS Funds | 3rd February, 2014
IFA Magazine – High Returns Don’t Always Mean High Risk
Mercia EIS Funds | 31st January, 2014
MFM featured in Growth Business on the need to increase the SEIS threshold
Mercia EIS Funds | 18th December, 2013
MFM mentioned in FT on why crowdfunding isn’t right for many start-ups
Mercia EIS Funds | 4th December, 2013
Simon Cartmell, healthcare expert and ex CEO of ApaTech, joins Mercia Fund Management Investment Panel
Mercia EIS Funds | 29th November, 2013
Autumn statement 2013: raise the seed funding cap or SMEs won’t flourish
Mercia EIS Funds | 27th November, 2013
Warwick Audio secures £1.25 million investment package
Mercia EIS Funds | 12th November, 2013
Mid-Stage Clinical Study of Wasting Disease Therapeutic MT-102 Shows Reversal of Cancer-Related Wasting
Mercia EIS Funds | 30th October, 2013
Mercia Fund Management holds Open House for companies seeking investment
Mercia EIS Funds | 25th October, 2013
Drug discovery services company CYP Design Ltd completes seed funding round
Mercia EIS Funds | 23rd October, 2013
Mercia Fund Management appoints Sales and Investor Relations Manager – Talon Golding
Mercia EIS Funds | 3rd October, 2013
PsiOxus Therapeutics named EuropaBio’s Most Innovative European Biotech SME
Mercia EIS Funds | 1st October, 2013
World First: The Native Antigen Company succeeds in manufacturing all four DENV NS1 serotypes from human cell lines
Mercia EIS Funds | 30th September, 2013
Mercia Fund Management makes first digital sector investment with Metric
Mercia EIS Funds | 18th September, 2013
Mercia Fund Management announces Mike Hayes as head of new digital division
Mercia EIS Funds | 21st August, 2013
Smart Antenna Technologies brings single antenna solution to cellular handsets
Mercia EIS Funds | 31st July, 2013
Antitope Announces Research Agreement with ChemomAb for Generation of Composite Human Antibodies against Inflammatory Diseases
Mercia EIS Funds | 29th July, 2013
Mercia Fund Management makes investment to help accelerate the growth of PolyTherics
Mercia EIS Funds | 24th July, 2013
Oxford Genetics secures funding for DNA cloning system
Mercia EIS Funds | 26th June, 2013
How Mercia Fund Management funds University of Keele spin-outs
Mercia EIS Funds | 24th June, 2013
PsiOxus Therapeutics initiates second clinical study of oncolytic vaccine
Mercia EIS Funds | 18th June, 2013
Ventive named national runner up in Shell Springboard awards 2013
Mercia EIS Funds | 23rd May, 2013
Irresistible Materials secures funding boost and new Chairman
Mercia EIS Funds | 9th May, 2013
Shell Springboard regional winner Ventive secures £900,000 funding
Mercia EIS Funds | 8th May, 2013
Dr Christine Wilkinson Blanc joins Psioxus Therapeutics as Chief Medical Officer
Mercia EIS Funds | 15th April, 2013
Mercia Fund Management announces Carlton Jones as nanoTherics’ CEO
Mercia EIS Funds | 9th April, 2013
Mercia Fund Management announces first SEIS investments from the Mercia Growth Fund 1
Mercia EIS Funds | 4th April, 2013
Oxford’s Native Antigen Company receives funding boost
Mercia EIS Funds | 27th March, 2013
Mercia Fund Management announces its first EIS investments from Mercia Growth Fund 1
Mercia EIS Funds | 25th March, 2013
Why SEIS is particularly attractive for 2013/14
Mercia EIS Funds | 15th March, 2013
Mercia Fund Management holds first Open House for SEIS and EIS investees
Mercia EIS Funds | 8th March, 2013
PolyTherics receives milestone payment as Celtic Pharma progresses development of long-acting version of Blood Factor VIII produced using PolyTherics’ TheraPEG™ technology
Mercia EIS Funds | 6th March, 2013
Mercia Fund Management launches Mercia Growth Fund 2 – a new hybrid EIS/SEIS investment opportunity
Mercia EIS Funds | 4th March, 2013
PsiOxus Therapeutics completes patient enrolment for Phase II wasting disease therapeutic MT-102